These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 7502685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S, Gülekli B, Turhan NO, Ozakşit G, Odabaşi AR, Oral H, Ozcan U, Gökmen O.
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [Abstract] [Full Text] [Related]

  • 3. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization.
    Mashiach S, Dor J, Goldenberg M, Shalev J, Levran D, Rudak E, Nebel L, Goldman B, Blankstein J, Ben-Rafael Z.
    Gynecol Endocrinol; 1989 Jun; 3(2):107-15. PubMed ID: 2816477
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R, Conway GS, Engmann L, Bekir JS, Jacobs HS.
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [Abstract] [Full Text] [Related]

  • 7. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B, Shaw RW, Iffland CA, Burford G, Bernard A.
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Good results of milder form of ovarian stimulation in an in vitro fertilization/intracytoplasmic sperm injection program.
    Grochowski D, Wołczyński S, Kuczyński W, Domitrz J, Szamatowicz J, Szamatowicz M.
    Gynecol Endocrinol; 1999 Oct; 13(5):297-304. PubMed ID: 10599545
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. LH supplementation in mild stimulations cycles without pituitary suppression: a retrospective analysis.
    Paragona M, Rossini M, Dattilo M, Stamm J.
    Gynecol Endocrinol; 2013 Feb; 29(2):101-4. PubMed ID: 23256611
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression.
    Edelstein MC, Brzyski RG, Jones GS, Simonetti S, Muasher SJ.
    Fertil Steril; 1990 Jan; 53(1):103-6. PubMed ID: 2104806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.